40 peptides FAQ

Add a direct lipolytic agent rather than increasing GH secretagogue dose. Plateaus after 8–10 weeks typically indicate receptor saturation. Higher CJC-1295 doses won't break the stall. AOD-9604 at 300 mcg daily works through a separate pathway (beta-3 adrenergic activation) and consistently restarts fat loss in plateaued patients. Alternatively, take a 2-week washout and resume at the original dose.

Yes, with monitoring. Growth hormone secretagogues can increase peripheral conversion of T4 to T3, potentially requiring thyroid dose adjustment. Check free T3 and TSH at baseline and week 8. If free T3 rises above the upper reference range while TSH remains suppressed, reduce levothyroxine by 12.5–25 mcg and retest in four weeks. The interaction is predictable and manageable, not a contraindication.

Reduce dose to 12.5 mg and ensure you're dosing before bed, not in the morning. MK 677 increases aldosterone and cortisol slightly, which drives sodium retention. This resolves within 2–3 weeks as the body adapts. If it doesn't, switch to injectable CJC-1295, which has lower aldosterone impact. Do not add diuretics. They mask the issue without addressing receptor adaptation.

Fasted training amplifies GH secretion naturally, so administering CJC-1295 and ipamorelin 30–45 minutes before a fasted morning session creates a compounded GH pulse. Higher amplitude and longer duration than either stimulus alone. The trade-off is that training in a fasted state without adequate post-workout protein intake can shift the body toward catabolic pathways despite elevated GH. The solution: administer peptides pre-training, complete the session, then consume 30–40 grams of protein within 60 minutes to capture the anabolic window while GH and IGF-1 are still elevated.

Yes, because testosterone and peptides address different bottlenecks. TRT restores androgen receptor activation, but it doesn't restore GH pulsatility or satellite cell proliferation rates. Those decline independently of testosterone levels. Combining TRT with CJC-1295 and ipamorelin produces additive effects: androgens improve contractile protein synthesis, while GH secretagogues improve recovery capacity and connective tissue remodeling. Research published in The Aging Male found that men on TRT who added GH secretagogue protocols gained 2.1 kg more lean mass over 16 weeks compared to TRT alone, despite identical training programs.

BPC-157 is the most relevant peptide for this scenario. Chronic joint pain after 40 is typically tendinopathy or cartilage degradation. Both conditions where collagen remodeling is the limiting factor. BPC-157 promotes VEGF expression and angiogenesis in hypovascular tissues like tendons, improving nutrient delivery and accelerating repair. Dosing 250–500 mcg daily for 4–6 weeks often reduces pain enough to allow progressive loading again. Importantly, BPC-157 doesn't mask pain like NSAIDs. It addresses the underlying tissue damage, so pain reduction correlates with actual healing rather than analgesia.